|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Delineation of epicardial stenosis in patients with microvascular disease using pressure drop coefficient:A pilot outcome study显示文摘AIM To investigate the patient-outcomes of newly developed pressure drop coefficient(CDP) in diagnosing epicardial stenosis(ES) in the presence of concomitant microvascular disease(MVD).METHODS Patients from our clinical trial were divided into two subgroups with:(1) cut-off of coronary flow reserve(CFR) < 2.0;and(2) diabetes.First,correlations were performed for both subgroups between CDP and hyperemic microvascular resistance(HMR),a diagnostic parameter for assessing the severity of MVD.Linear regression analysis was used for these correlations.Further,in each of the subgroups,comparisons were made between fractional flow reserve(FFR) < 0.75 and CDP > 27.9 groups for assessing major adverse cardiac events(MACE:Primary outcome).Comparisons were also made between the survival curves for FFR < 0.75 and CDP > 27.9 groups.Two tailed chi-squared and Fischer's exact tests were performed for comparison of the primary outcomes,and the log-rank test was used to compare the Kaplan-Meier survival curves.P < 0.05 for all tests was considered statistically significant.RESULTS Significant linear correlations were observed between CDP and HMR for both CFR < 2.0(r = 0.58,P < 0.001) and diabetic(r = 0.61,P < 0.001) patients.In the CFR < 2.0 subgroup,the %MACE(primary outcomes) for CDP > 27.9 group(7.7%,2/26) was lower than FFR < 0.75 group(3/14,21.4%);P = 0.21.Similarly,in the diabetic subgroup,the %MACE for CDP > 27.9 group(12.5%,2/16) was lower than FFR < 0.75 group(18.2%,2/11);P = 0.69.Survival analysis for CFR < 2.0 subgroup indicated better event-free survival for CDP > 27.9 group(n = 26) when compared with FFR < 0.75 group(n = 14);P = 0.10.Similarly,for the diabetic subgroup,CDP > 27.9 group(n = 16) showed higher survival times compared to FFR group(n = 11);P = 0.58.CONCLUSION CDP correlated significantly with HMR and resulted in better %MACE as well as survival rates in comparison to FFR.These positive trends demonstrate that CDP could be a potential diagnostic endpoint for delineating MVD with or without ES. | Ullhas Udaya Hebbar Mohamed A Effat Srikara V Peelukhana Imran Arif Rupak K Banerjee | 2017 | World Journal of Cardiology2017，9，12： | 2 |
| 2 | Studies on NPK drip fertigation in field grown tomato (Lycopersicon esculentum Mill显示文摘 | Hebbar S S Ramachandrappa B K Nanjappa H V | 2004 | European Journal of Agronomy2004，21，1： | 1 |
| 3 | Studies on NPK drip fertigation in field grown tomato显示文摘 | Hebbar S S Ramachandrappa B K Nanjappa H V | 2004 | European Journal of Agronomy2004，21，1： | 1 |
| 4 | Differential expression of MUC genes in endometrial and cervical' tissues and tumors 显示文摘 | Hebbar V Damera G Sachdev G P | 2005 | BMC Cancer2005，5，： | 1 |
| 5 | Prognostic value of the type Ⅰ growth factor receptor in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay 显示文摘 | Pawlowski V Revillion F Hebbar M | 2000 | Clin Cancer Res2000，6，11： | 1 |
| 6 | Prognostic value of the type Ⅰ growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcriptionpolymerase chain reaction assay显示文摘 | Pawlowski V Revillion F Hebbar M | 2000 | Clin Cancer Res2000，6，11： | 1 |
| 7 | Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay 显示文摘 | Pawlowski V Revillion F Hebbar M | 2000 | Clin cancer Res2000，6，11： | 1 |
| 8 | Resveratrol In- hibits Phorbol Ester and UV-induced Activator Protein 1 Activation by Interfering with Mitogen activated Protein Kinase Pathways显示文摘 | YU R HEBBAR V KIM D W | 2001 | Molecular Pharmacolo- gy2001，60，1： | 1 |
| 9 | Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay显示文摘 | PAWLOWSKI V R(E)VILLION F HEBBAR M | 2000 | Clin Cancer Res2000，6，11： | 1 |
| 10 | In vivo pharmacokinetics and regulation of gene expression profiles by isothioeyanate sulforaphane in the rat显示文摘 | Hu R Hebbar V Kim BR | 2004 | J Pharmacol Exp Ther2004，310，： | 1 |
| 11 | Synergistic effects of a combination of dietary factors sulforaphane and(-)epigallocatechin-3-gallate in HT-29 AP-1human colon carcinoma cells显示文摘 | Nair S Hebbar V Shen G | 2008 | Pharm Res2008，25，2： | 1 |
| 12 | Studies on NPK drip fertigation in field grown tomato ( Lycopersicon escu- lentum Mill) 显示文摘 | Hebbar S S Ramachandrappa B K Nanjappa H V | 2004 | European Journal of Agronomy2004，21，1： | 1 |
| 13 | Metabolism,oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats显示文摘 | Barve A Chen C Hebbar V | 2009 | Biopharm Drug Dispos2009，30，7： | 1 |
| 14 | Differential expression of MUC genes in endometrial and cervical tissues and tumors显示文摘 | Hebbar V Damera G Sachdev GP | 2005 | BMC Cancer2005，5，1： | 1 |
| 15 | Prognostic value of the type 1 growth factor receptors in a large series of hu-man primary breast cancers quantified with a real-time re-verse transcription-polymerase chain reaction assay显示文摘 | Pawlowski V Revillion F Hebbar M | 2000 | Clin Cancer Res2000，6，11： | 1 |
| 16 | In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat 显示文摘 | Hu R Hebbar V Kim BR | 2004 | J Pharmacol Exp Ther2004，310，： | 1 |
| 17 | Resveratrol inhibits phorbolester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways 显示文摘 | Yu R Hebbar V Kim DW | 2001 | Mol Pharmacol2001，60，1： | 1 |
| 18 | Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways 显示文摘 | Yu R Hebbar V Kim DW | 2001 | Molecular Pharmacol2001，60，1： | 1 |
| 19 | Synergistic effects of a combination of dietary factors sulforaphane and (-) epigallocatechin-3-gallate in HT-29 AP-1 human colon carcinoma cells显示文摘 | Nair S Hebbar V Shen G | 2008 | Pharm Res2008，25，2： | 1 |
| 20 | In vivo pharmacokinetics and reg- ulation of gene expression profiles by isothiocyanate sulforaphane in the rat 显示文摘 | Hu R Hebbar V Kim BR | 2004 | J Pharmacol Exp Ther2004，310，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员